ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess DV-601 in Subjects With Chronic Hepatitis B

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01023230
Recruitment Status : Completed
First Posted : December 2, 2009
Last Update Posted : March 1, 2018
Sponsor:
Information provided by (Responsible Party):
Dynavax Technologies Corporation

Brief Summary:
The purpose of this study is to determine if DV-601, an investigational, therapeutic vaccine will be well-tolerated and induce hepatitis B virus (HBV)-specific virological and immunological responses in chronic hepatitis B (CHB) patients.

Condition or disease Intervention/treatment Phase
Hepatitis B, Chronic Drug: DV-601 Drug: Entecavir Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib Dose-Escalation Study to Assess the Safety and Tolerability of DV-601 in Subjects With Chronic Hepatitis B on Concurrent Treatment With a Nucleoside Analogue
Study Start Date : September 2009
Actual Primary Completion Date : May 2011
Actual Study Completion Date : May 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Entecavir

Arm Intervention/treatment
Experimental: DV-601 Drug: DV-601
Six injections of DV-601 administered over a period of 12 weeks.

Drug: Entecavir
Daily dosing starting approximately 4 weeks prior to first dose of DV-601 for one year total duration.
Other Name: Baraclude




Primary Outcome Measures :
  1. Patient diaries, adverse events, physical exams, and lab tests [ Time Frame: Through Day 99 ]

Secondary Outcome Measures :
  1. HBV-DNA levels [ Time Frame: Change from baseline to Days 43 and 99, and to Weeks 24 and 48 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female subjects 18 to 65 years of age.
  • Signed informed consent.
  • Diagnosis of CHB and candidates for therapy
  • Normal renal function
  • Women of childbearing potential must have a serum negative pregnancy test at screening. Women of childbearing potential and males whose sexual partners are of childbearing potential must agree to use dual methods of contraception.

Exclusion Criteria:

  • Liver disease other than CHB
  • Documented co-infection with hepatitis A virus (HAV), hepatitis C virus (HCV), or HIV
  • Previous therapy with interferon alpha.
  • Any other antiviral therapy for chronic hepatitis B within the previous 3 months prior to Screening Visit.
  • Immunosuppressive treatment (e.g. chemotherapy, high-dose of steroids) within 6 months of Screening Visit.
  • Evidence of cirrhosis
  • Child-Turcotte-Pugh (CTP) score ≥ 7, either currently or at any occasion in the past
  • Clinically significant acute or chronic illnesses, such as autoimmune diseases, collagen vascular disease, immune deficiencies, active or uncontrolled infections, etc. as determined by the investigator and documented in medical history.
  • Malignancy other than curatively treated, superficial skin cancer or carcinoma in situ of the cervix.
  • Participation in any experimental protocol or therapy within 28 days prior to the Screening Visit.
  • Current substance or alcohol abuse that in the opinion of the investigator would interfere with compliance or with interpretation of study results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01023230


Locations
Poland
Collegium Medicum Uniwersytet im. Mikołaja Kopernika
Bydgoszcz, Poland, 85-030
Samodzielny Publiczny Wojewódzki Szpital Zespolony
Szczecin, Poland, 71-455
Wojewódzki Szpital Zakaźny
Warsaw, Poland, 01-201
NZOZ Centrum Badan Klinicznych
Wrocław, Poland, 50-349
Sponsors and Collaborators
Dynavax Technologies Corporation

Responsible Party: Dynavax Technologies Corporation
ClinicalTrials.gov Identifier: NCT01023230     History of Changes
Other Study ID Numbers: DV4-HBT-02
2009-010142-66 ( Registry Identifier: EudraCT )
First Posted: December 2, 2009    Key Record Dates
Last Update Posted: March 1, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: a/o August 2016, decision is still pending.

Keywords provided by Dynavax Technologies Corporation:
DV-601
hepatitis B
entecavir
therapeutic vaccine

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis, Chronic
Hepatitis B
Hepatitis B, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Entecavir
Antiviral Agents
Anti-Infective Agents